Enterogermina Dosing
For acute diarrhea in children, administer Bacillus clausii (Enterogermina) at 2 billion spores (one 5 mL vial) twice daily for 5-7 days; for adults and adolescents, use 2 billion spores three times daily for up to 14 days.
Pediatric Dosing (Infants and Children)
Standard regimen for acute diarrhea:
- Dose: 2 billion spores per 5 mL vial
- Frequency: Twice daily (morning and evening)
- Duration: 5-7 days
- Age range: 6 months to 5 years 1, 2
For higher severity cases or persistent diarrhea, higher dosing has been studied:
- High-dose regimen: 4-6 vials per day (8-12 billion spores total daily)
- This showed significantly faster recovery (2 days shorter) in persistent diarrhea 3
Adult and Adolescent Dosing
For antibiotic-associated diarrhea prevention:
- Dose: 2 billion spores (one capsule or vial)
- Frequency: Three times daily
- Duration: Throughout antibiotic course, up to 14 days 4, 5
For acute diarrhea treatment:
- Dose: 2 billion spores per vial
- Frequency: 2-3 times daily
- Duration: 5-7 days
Clinical Context and Administration
The evidence consistently supports twice-daily dosing in children for acute gastroenteritis, with the product well-tolerated across large populations 2. In the Philippine multicenter study of 3,178 children, this regimen resulted in diarrhea resolution within 3 days in over half of patients, with mean duration of 3.3-3.4 days 2.
Key administration points:
- Administer orally only - never intravenously (one case report documented severe systemic inflammatory response from accidental IV administration) 6
- Can be given with or without zinc supplementation
- Compatible with oral rehydration therapy
- May be more effective when used without concurrent zinc (3.3 vs 3.6 days to resolution) 2
Important Safety Considerations
While generally safe, rare cases of bacteremia have been reported in immunocompromised patients 7. The product should be used cautiously in severely immunocompromised individuals or those with central venous catheters.
The formulation contains spore-forming bacteria resistant to most antibiotics, making it suitable for concurrent use during antibiotic therapy 4.